Cargando…
PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer
It has recently been proposed that a three-gene model (SCMGENE) that measures ESR1, ERBB2, and AURKA identifies the major breast cancer intrinsic subtypes and provides robust discrimination for clinical use in a manner very similar to a 50-gene subtype predictor (PAM50). However, the clinical releva...
Autores principales: | Prat, A., Parker, J. S., Fan, C., Perou, C. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413822/ https://www.ncbi.nlm.nih.gov/pubmed/22752290 http://dx.doi.org/10.1007/s10549-012-2143-0 |
Ejemplares similares
-
PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
por: Bastien, Roy RL, et al.
Publicado: (2012) -
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
por: Wallden, Brett, et al.
Publicado: (2015) -
Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay
por: Hurson, Amber N., et al.
Publicado: (2023) -
Multi-Omic Regulation of the PAM50 Gene Signature in Breast Cancer Molecular Subtypes
por: Ochoa, Soledad, et al.
Publicado: (2020) -
Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status
por: Prat, Aleix, et al.
Publicado: (2014)